Participating in a Phase 2 trial since June 2021 that includes a maintenance phase of 200mg of Nariparib orally daily and once monthly intravenous injection 30mg/ml of Cetrelimab. The Trial initially included six cycles (Induction Phase) of Cabazitaxel/Carboplatin/Cetrelimab.
Throughout this timeframe my PSA has risen from 4.4 in May 2021 to now 14.65 as of yesterday. My CEA has also elevated from 8.1 in December 2021 to 13.9 as of yesterday.
My MO continues to state that I should not pay attention to these markers, that the CT and Full Body Bone Scans will dictate whether or not the trial meds are helping or not. As one might imagine however, it is extremely difficult to ignore these markers given the velocity of increase over such a relatively short period of time.
Any one have any suggestions for discussion with my MO on continuing in the trial or exploring appropriate alternatives ?